Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Reed Miller
Medtronic says that most of the clinical trials it is sponsoring are paused due to the pandemic, which means the completion of its PMA application for the Symplicity Spyral renal denervation system will be delayed.
Three-month results of the SPYRAL HTN-OFF MED pivotal trial show renal denervation with Medtronic’s Symplicity Spyral system significantly reduced blood pressure in hypertensive patients not taking anti-hypertensive medications.
Butterfly Network is disseminating the lessons from China and Italy about the poential value of lung ultrasound in the management of COVID-19 patients with respiratory disease.
As the pandemic unfolds with an uncertain outcome, US securities analysts that cover publicly traded medtech companies are developing mathematical models to estimate the impact of the COVID-19 pandemic on medtech companies.
The Texas company is planning to sell 30,000 at-home sample collection kits for COVID-19 testing beginning on 23 March.
In this episode of our weekly podcast, Medtech Insight managing editor Marion Webb talks with deputy editor Reed Miller about her story on US hospitals canceling elective surgeries to preserve critical resources in response to COVID-19, and hospitals joining forces with medtechs to find rapid technological solutions to keep patients and caregivers healthy.